Welcome to our dedicated page for Lifemd news (Ticker: LFMDP), a resource for investors and traders seeking the latest updates and insights on Lifemd stock.
News for LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP) is closely tied to developments at LifeMD, Inc., the issuer of this preferred security. LifeMD regularly publishes updates about its virtual primary care and pharmacy operations, financing activities, and corporate governance, all of which can be relevant to investors following LFMDP.
Company announcements describe LifeMD as a provider of virtual primary care services and pharmacy solutions, with telemedicine, laboratory access, and pharmacy services supporting treatment across more than 200 conditions. News items highlight growth in telehealth revenue, expansion into areas such as weight management, women’s health, mental and behavioral health, and cardiometabolic care initiatives, and the evolution of its virtual care platform.
Investors tracking LFMDP can expect news related to LifeMD’s clinical programs, including collaborations with pharmaceutical manufacturers. Recent releases discuss expanded collaboration with Novo Nordisk, access to Wegovy and Ozempic within LifeMD’s weight management program, and the addition of the Wegovy pill to its virtual obesity care offering. Other updates cover developments in women’s health programs, including the appointment of clinical advisors, and the scaling of men’s health and RexMD-branded services.
Corporate and financial news is also significant for LFMDP followers. LifeMD has issued press releases on quarterly financial results, changes in independent registered public accounting firms, the divestiture of its majority interest in WorkSimpli Software LLC to focus on virtual care and pharmacy, and the establishment of a revolving credit facility. The company has additionally announced quarterly cash dividends on the 8.875% Series A Cumulative Perpetual Preferred Stock.
By reviewing the LFMDP news feed, readers can monitor how LifeMD’s virtual care strategy, partnerships, financial decisions, and governance updates may influence the context in which this preferred stock operates. Regular news provides a consolidated view of operational milestones and capital structure developments that matter to preferred and common equity holders alike.
LifeMD (Nasdaq: LFMD) has announced major enhancements to its weight management program, expanding patient access to branded GLP-1 therapies and introducing new treatment options. The company has implemented a real-time electronic benefit verification program and partnered with an AI-powered platform to optimize prior authorization submissions. These improvements are estimated to increase LifeMD's addressable weight loss market by 15%.
Key advancements include:
- Integration of at-home, self-collection laboratory testing services
- Launch of a personalized therapy alternative to GLP-1 medications
- Improved pharmacy benefits infrastructure
Over the past 30 days, 38% of patients providing insurance information received affordable coverage for branded GLP-1 medication, with expectations to exceed 50% soon.
LifeMD (Nasdaq: LFMD), a leading virtual primary care provider, has announced its participation in three major investor conferences in September 2024. The company's management will attend:
1. H.C. Wainwright 26th Annual Global Investment Conference (Sept. 9-11) in New York, featuring a corporate presentation on Sept. 9 at 12:00 p.m. ET.
2. TD Cowen 9th Annual FutureHealth Conference (Sept. 10) in New York, participating in a panel discussion at 2:20 p.m. ET.
3. Cantor Fitzgerald Global Healthcare Conference (Sept. 17-19) in New York, with a fireside chat on Sept. 18 at 8:35 a.m. ET.
At these events, LifeMD's management will engage in one-on-one meetings with investors, showcasing the company's progress and future prospects in the virtual healthcare sector.
LifeMD (LFMD) reported strong Q2 2024 results, with revenue increasing 41% year-over-year to $50.7 million. Telehealth revenue grew 67%, and the segment achieved profitability one quarter ahead of guidance with adjusted EBITDA of $820,000. Key highlights include:
- Telehealth active subscribers increased 32% to 254,000
- Weight management subscribers exceeded 60,000
- Gross margin expanded to 90%
- Adjusted EBITDA increased 44% to $2.5 million
- Cash position of $35.7 million as of June 30, 2024
The company raised its 2024 telehealth revenue guidance to $150 million and introduced telehealth adjusted EBITDA guidance of $3-4 million. However, due to WorkSimpli's underperformance, consolidated adjusted EBITDA guidance was revised to $13-15 million.
LifeMD (Nasdaq: LFMD), a leading virtual primary care provider, has announced it will release its Q2 2024 financial results on August 7, 2024, after U.S. financial markets close. The company will host a conference call at 4:30 p.m. Eastern time on the same day to discuss the results. Investors can access the call via toll-free (1-800-245-3047) or international (1-203-518-9765) dial-in numbers, using the conference ID: LIFEMD. A live and archived webcast of the call will also be available.
LifeMD (Nasdaq: LFMD), a leading virtual primary care provider, has announced its participation in two major investor conferences in August 2024. The company will attend the KeyBanc Capital Markets Technology Leadership Forum from August 4-6 in Vail, Colorado, where management will engage in a fireside chat on August 5th and conduct one-on-one investor meetings.
Additionally, LifeMD will be present at the Canaccord Genuity 44th Annual Growth Conference from August 13-15 at the InterContinental Boston hotel. During this event, the management team will deliver a corporate overview on August 14th and hold individual meetings with investors. These conferences provide LifeMD with valuable opportunities to showcase its business model and growth strategies to potential investors and industry analysts.
LifeMD (NASDAQ: LFMD/LFMDP) has announced a quarterly cash dividend for its 8.875% Series A Cumulative Perpetual Preferred Stock. The dividend amounts to $0.5546875 per share and will be paid on July 15, 2024, to shareholders of record as of July 5, 2024. This marks a continued commitment to providing returns to shareholders.
LifeMD (Nasdaq: LFMD) has launched the acceptance of private health insurance for its virtual primary care services, including weight management, in selected states. This initiative aims to provide broader coverage options nationwide by 2025, with plans to start accepting Medicare early next year. The company intends to enhance access to high-quality, affordable care and improve clinical outcomes and patient retention rates through this phased rollout. Initially, patients will benefit from significantly reduced out-of-pocket costs for non-covered services, coupled with a streamlined claims submission and prior authorization process.
LifeMD (Nasdaq: LFMD) will participate in the Truist Securities Healthcare Disruptors & Digital Health Summit on June 25-26, 2024, at the Lotte New York Palace, New York City. CEO Justin Schreiber will join a panel discussion on “Weight Management/Diabetes Care: Tools to Manage Cost vs Benefit.” Additionally, LifeMD management will hold one-on-one meetings with institutional investors. Interested investors should contact their Truist Securities representative for more details.
LifeMD (Nasdaq: LFMD) will join the Russell 3000 Index after the 2024 Russell U.S. Indexes annual reconstitution. This inclusion will take effect at the start of U.S. equity markets on July 1, 2024. The Russell 3000 Index captures the 4,000 largest U.S. stocks by market capitalization. Membership means automatic inclusion in either the Russell 1000 or Russell 2000 Index, along with the corresponding growth and value style indexes. This inclusion reflects LifeMD's growth in providing affordable primary care and other healthcare services. The Russell indexes, managed by FTSE Russell, serve as benchmarks for approximately $10.5 trillion in assets. The annual rebalancing ensures the indexes accurately represent market segments.
LifeMD reported a strong first quarter of 2024 with a 33% revenue increase year-over-year to $44.1 million. Telehealth revenue grew by 53% compared to the previous year. The company raised full-year revenue guidance to at least $205 million, showing growth in all business segments. Weight management subscribers surpassed 50,000, with cash-adjusted EBITDA at $4.8 million, a 108% increase. The company generated $5.2 million in cash flow and had a $2.0 million net increase in cash during the quarter.